AR antagonists in combination with inhibitors of additional STS-molecular targets (e.g., EGFR and/or AR/Src complex) might emerge as a novel therapeutic strategy, since STS frequently exhibit derangements of EGFR and tyrosine kinase signaling ([12,13] and refs therein). The gene discussed is EGFR; the disease is telomere syndrome.